Related references
Note: Only part of the references are listed.Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia
Sergio A. Giralt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkela et al.
NATURE MEDICINE (2006)
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study
M Bornhauser et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era:: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study
GJ Ruiz-Argüelles et al.
BONE MARROW TRANSPLANTATION (2005)
Imatinib therapy prior to myeloablative allogeneic stem cell transplantation
JM Zaucha et al.
BONE MARROW TRANSPLANTATION (2005)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Imatinib mesylate (ST1571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias
A Shimoni et al.
LEUKEMIA (2003)
Share Paper
